Replies to post #222189 on Biotech Values

[DewDiligence]

NTGN doses first patient in phase-1b trial:

https://finance.yahoo.com/news/neon-therapeutics-apexigen-announce-first-120000827.html

The Phase 1b trial is evaluating NEO-PV-01 and nivolumab in combination with other agents in first-line patients with advanced or metastatic melanoma. One arm of the multi-arm study will evaluate the vaccine and nivolumab in combination with Apexigen's APX005M, an investigational CD40 agonist. Another will evaluate NEO-PV-01 and nivolumab in combination with ipilimumab.

[DewDiligence]

NTGN 4Q18 results—cash=$103M:

https://www.globenewswire.com/news-release/2019/03/11/1751073/0/en/Neon-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Business-Update.html

No CC.